Skip to content

Innovation

Mass General Brigham spin-off, Adheron, is acquired by Roche for $580 million. When pharmaceutical giant Roche announced plans to acquire Mass General Brigham spinoff Adheron Therapeutics in September, immunologist Michael Brenner, MD, couldn't help but recall the unlikely events that inspired the spinoff. The original spark that ignited Adheron's promising therapy for inflammatory and autoimmune…

Read More

Mass General Brigham Spin-off, GeneInsight, makes personalized medicine a reality for patients throughout the United States. Dazzling discoveries in genomics and genetics are ushering in new possibilities for precision medicine. But simmering beneath the surface of this excitement is a layer of uncertainty: As researchers expand the list of disease-associated genes, laboratories are debating the…

Read More

A look at the promising oncology therapeutics under exploration by Mass General Brigham spin-off, Raze Therapeutics. A new approach to treating certain cancers may lie in an often-overlooked corner of amino acid metabolism, according to the science behind a new Mass General Brigham spinoff. Promising oncology therapeutics under exploration by Raze Therapeutics aim to dismantle…

Read More

Mass General Brigham spinoff, Annovation BioPharma's next-generation intravenous anesthetic, ABP700, garnered promising clinical results and is expected to be acquired by The Medicines Company in early 2015. The Massachusetts General Hospital has been celebrated worldwide for nearly 200 years of anesthetic innovation – the iconic image of the Ether Dome surgery is hallowed throughout the…

Read More

Earlier this fall, Mass General Brigham spinoffs Editas Medicine and Spero received global recognition. Earlier this fall, Mass General Brigham spinoffs Editas Medicine and Spero received global recognition when they were named to the prestigious Fierce Biotech's Fierce 15, an annual compilation of leading biotech upstarts. Researchers around the globe are pursuing various strategies for…

Read More

Mass General Brigham spin-off, CoStim Pharmaceuticals, positioned to be a leader in the immune checkpoint regulation market. With excitement growing around immune checkpoint regulation as a major advance in treating cancer, the emergence of Mass General Brigham spin-off CoStim Pharmaceuticals could not be better timed. Industry experts expect the immune checkpoint therapy market will continue…

Read More

A look into the future of Daktari Diagnostics and their handheld CD4 cell counter. Daktari Diagnostics' slogan says it all: “Today There is No Place Out of Reach.” When it officially launches in the first quarter of 2014, Daktari's handheld CD4 cell counter will enable millions of people in developing nations living with HIV to…

Read More